Powered by OpenAIRE graph
Found an issue? Give us feedback
image/svg+xml art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos Open Access logo, converted into svg, designed by PLoS. This version with transparent background. http://commons.wikimedia.org/wiki/File:Open_Access_logo_PLoS_white.svg art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos http://www.plos.org/ Trends in Pharmacolo...arrow_drop_down
image/svg+xml art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos Open Access logo, converted into svg, designed by PLoS. This version with transparent background. http://commons.wikimedia.org/wiki/File:Open_Access_logo_PLoS_white.svg art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos http://www.plos.org/
Trends in Pharmacological Sciences
Article . 2025 . Peer-reviewed
License: CC BY NC
Data sources: Crossref
https://pubmed.ncbi.nlm.nih.go...
Article
Data sources: Europe PubMed Central
 View all 2 versions
Claim

Nemolizumab (Nemluvio®) for prurigo nodularis

descriptionPublicationkeyboard_double_arrow_right Article 01 Sep 2025 English Publisher:Elsevier BVJournal:Trends in Pharmacological Sciences, volume 46, pages 922-923 (issn: 0165-6147, Copyright policy )
Authors: Svenja, Royeck; Sonja, Ständer;

doi: 10.1016/j.tips.2025.06.004

pmid: 40619305

Nemolizumab (Nemluvio®) for prurigo nodularis

No summary information available
Powered by OpenAIRE graph
Found an issue? Give us feedback